The following table disaggregates revenue by global product category for the three and nine months ended September 30, 2018 and October 1, 2017.



	Three Months Ended				Nine Months Ended
	September 30, 2018		October 1, 2017		September 30, 2018		October 1, 2017
Revenue by global product category_{(1) (2)}	(Dollars in thousands)
Vascular access	$	142,712	$	133,521	$	427,557	$	396,866
Anesthesia	87,973		87,964		263,202		255,107
Interventional	79,404		69,186		228,262		181,577
Surgical	89,910		85,210		266,049		263,254
Interventional urology	48,995		—		138,969		—
OEM	54,838		48,589		153,286		137,067
Other₍₃₎	105,840		110,233		329,443		317,326
Net revenues	$	609,672	$	534,703	$	1,806,768	$	1,551,197

(1)

The product categories listed above are presented on a global basis; in contrast, the Company’s North American reportable segments generally are defined largely based on the particular products sold by the segments, and its non-North American reportable segments are defined exclusively based on the geographic location of segment operations (with the exception of the Original Equipment and Development Services ("OEM") reportable segment, which operates globally). The Company’s EMEA and Asia reportable segments, as well as its Latin America operating segment, include net revenues from each of the product categories listed above.

(2)

The methodology used to determine the product revenues included within certain of the product categories listed in the table above differs from the methodology used to classify revenues in our reportable segments, including the similarly named North American reportable segments. The differences are due to the fact that segment classification generally is determined based on the call point within the customer's organization from which the purchase order resulting in the sale originated, while the classification of products within the product categories listed in the table above includes all sales of products within the listed product category, regardless of the call point within the customer's organization from which the sale originated.

(3) Other revenues in the table above include revenues related to sales of the Company’s respiratory, urology and cardiac products.